Thrilled to announce that C-Path CEO Klaus Romero will deliver the keynote at this year's NATIONAL NIEMANN-PICK DISEASE FOUNDATION- Family Support Conference in Salt Lake City this Friday, July 12. Klaus will also join the expert panel discussion on "Policy and Drug Development in Patient Care Related to Niemann-Pick Disease" on July 13. C-Path's Critical Path for Lysosomal Diseases Consortium collaborates with #NNPDF, other patient advocacy groups, pharmaceutical companies, and regulatory agencies like the FDA to identify and prioritize solutions in drug development for lysosomal and other inherited metabolic diseases. CPLD Scientific Director Krista Casazza will also be in attendance. Don't hesitate to reach out to her and Klaus if you'll be at the conference. We look forward to connecting with you! #CPath #niemannpick #lysosomal #globalhealth #collaboration #metabolicdisease #drugdevelopment #datasharing
Critical Path Institute (C-Path)
Research Services
Tucson, AZ 7,737 followers
Advancing Drug Development. Improving Lives. Together.
About us
Critical Path Institute (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership, in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.
- Website
-
http://www.c-path.org/
External link for Critical Path Institute (C-Path)
- Industry
- Research Services
- Company size
- 51-200 employees
- Headquarters
- Tucson, AZ
- Type
- Nonprofit
- Founded
- 2005
- Specialties
- creating collaborations with regulators, patient advocacy groups and the regulated pharmaceutical industry, accelerated development of safer, new medical products, faster, safer, and smarter medical product development, and public private partnership
Locations
-
1840 E River Rd # 100
Tucson, AZ 85718, US
-
Barbara Strozzilaan 201 1083 HN
Amsterdam, NL
Employees at Critical Path Institute (C-Path)
-
Deb Discenza (she/her/hers)
-
Thomas Morel
Global Patient-Centred Outcomes Research & Policy Lead at UCB
-
Huong Huynh Reagan
FDA alum working to facilitate pre-competitive collaborations to advance clinical trials and accelerate drug development in rare diseases.
-
Hannah Blau
Data Scientist ∙ ML / NLP Engineer ∙ Listener Extraordinaire ∙ She who does not let stuff fall through the cracks
Updates
-
Early 🦅 bird pricing ends on July 15! REGISTER NOW for the inaugural C-Path Global Impact Conference. Taking place September 9-11, in Washington D.C., this Conference promises to provide a unique opportunity to integrate key learnings across initiatives within C-Path’s expanding portfolio, dedicated to accelerating drug development for conditions in neurology, rare diseases, pediatrics, and more. Your participation at past program-specific meetings has been instrumental in driving forward the convergence of this meeting, and we look forward to continuing this important work together. Please register now and join us for another inspiring and impactful event! Register now and learn more: https://lnkd.in/g4TqwJVR #CPath #CGIC2024 #GlobalImpactConference #drugdevelopment #datasharing #collaboration #neurology #pediatrics #raredisease
-
-
Upcoming Webinar: The Influential Role of Patient Advocacy Groups in Registry Data Efforts Join us on Thursday, July 18, at 12 p.m. ET for an insightful webinar hosted by C-Path's Mitochondrial and Inherited Metabolic Diseases Task Force. Discover how patient advocacy groups are pivotal in driving registry data efforts for mitochondrial and inherited metabolic diseases, ensuring that patient experiences and outcomes are central to research and regulatory decision-making. Our presenters include: Sophia Zilber 🌺Board Member and Patient Registry Director, Cure Mito Foundation. Sophia brings over 20 years of experience in drug development and clinical data analysis, leading the global Leigh syndrome patient registry at the Cure Mito Foundation. Elizabeth Reynolds, Co-Founder and Executive Director, The Champ Foundation. Dr. Reynolds has spearheaded over $2 million in research grants for Single Large-scale mtDNA Deletion Syndromes and co-leads a multi-site Natural History Study and patient-registry. Amanda Klein, Executive Director, Critical Path for Lysosomal Diseases and the Alpha-1 Antitrypsin Deficiency Consortia at C-Path. Dr. Klein leads initiatives to accelerate drug development for mitochondrial and inherited metabolic diseases and is a key figure in the RDCA-DAP initiative. Don’t miss this opportunity to learn from experts about the crucial role of patient advocacy in advancing research and healthcare outcomes. 🔗 Register now to secure your spot: https://lnkd.in/eNExmF9R #CPath #PatientAdvocacy #MitochondrialDiseases #Webinar #HealthcareInnovation #DrugDevelopment #collaboration #datasharing
-
-
JOIN US Thursday, July 18, for an in-depth look at the key considerations around the use of Bring Your Own Device (BYOD) approaches to electronic clinical outcome assessment data collection in clinical trials, developed and presented by members of the BYOD Project Team as part of the eCOA Consortium and PRO Consortium’s eCOA: Getting Better Together Initiative. Register now: https://lnkd.in/enx2u4Xb Karl McEvoy Kelly Dumais Chris Barden Heather Romero Scottie Kern eCOA members, include: ActiGraph Evinova Clario ICON plc Inspired Health IQVIA Kayentis Koneksa Mapi Research Trust Medable, Inc Medidata Solutions Medrio ObvioHealth Parexel Red Nucleus RWS Group Signant Health Suvoda TransPerfect Life Sciences uMotif WCG YPrime #CPath #eCOA #DHT #ACT #eCOAC #globalhealth #collaboration #drugdevelopment #datasharing #clinicaltrials
-
-
🔍 How can #AI and #ML approaches help identify and appraise registries and relevant data? Join us for an insightful webinar on Tuesday, July 9 at 3 PM CET to find out! We are honored to host distinguished speakers and regulatory experts: ▶ Peter Mol, More-EUROPA ▶ Luis Correia Pinheiro, European Medicines Agency ▶ Nicolas Löffler-Perez , PhD, Swissmedic ▶ Ghinwa Hayek, Quinten Health ▶ Billy AMZAL, Quinten Health Don't miss this opportunity to learn from the best in the field! 👉 Secure your spot now: https://lnkd.in/e2MeSqjU #CPath #CPathEurope #drugdevelopment #datasharing #collaboration #HealthData #Healthcare #MachineLearning #RegulatoryScience Klaus Romero Cécile Ollivier Eva Fernandez Kimberly Ward Barowicz Sieta de vries Lysbeth Bakker Carla Torre Bruno Sepodes
-
-
Interested in C-Path updates? Be sure to subscribe at https://lnkd.in/g98uYmxV For 20 years, C-Path has been providing vital infrastructure to generate a neutral environment for everyone working in drug development to collaborate, not compete. Let's improve lives, together. #CPath #drugdevelopment #neutral #datasharing #globalhealth #collaboration #regulatoryscience
-
Early 🦅 bird pricing ends on July 15! REGISTER NOW for the inaugural C-Path Global Impact Conference. Taking place September 9-11, in Washington D.C., this Conference promises to provide a unique opportunity to integrate key learnings across initiatives within C-Path’s expanding portfolio, dedicated to accelerating drug development for conditions in neurology, rare diseases, pediatrics, and more. Your participation at past program-specific meetings has been instrumental in driving forward the convergence of this meeting, and we look forward to continuing this important work together. Please register now and join us for another inspiring and impactful event! Register now and learn more: https://lnkd.in/g4TqwJVR #CPath #CGIC2024 #GlobalImpactConference #drugdevelopment #datasharing #collaboration #neurology #pediatrics #raredisease
-
-
Wishing our amazing LinkedIn community a fun and safe 4th! 🎆 #CPath #collaboration #drugdevelopment #datasharing #globalhealth
-
🎗 July is Sarcoma Awareness Month and the C-Path team is proudly wearing their Lane United FC jerseys to support tonight's game in Eugene, Oregon. We stand united with the team and community to raise awareness for sarcoma and show our support for all those affected by this rare cancer. Join us in spreading awareness and cheering on Lane United FC! Let's make a difference together. For more on John R. Galas inspiring journey and how he’s battling sarcoma with the same determination he brings to soccer, read his impact story here: https://lnkd.in/gGWUuhEa Lane United FC xCures CURE ID hummel Anna Galas Kristen Swingle Mark Drew Claire Bassetti Alexander Diegel Dave Galas Kristopher Michael Wood #CPath #LaneUnitedFC #UnitedAgainstCancer #xCures #hummel #CDRC #ImpactStory #Sarcoma #SarcomaAwareness #DrugDevelopment #DrugRepurposing #DataSharing #GlobalHealth
-
Upcoming Webinar: The Influential Role of Patient Advocacy Groups in Registry Data Efforts Join us on Thursday, July 18, at 12 p.m. ET for an insightful webinar hosted by C-Path's Mitochondrial and Inherited Metabolic Diseases Task Force. Discover how patient advocacy groups are pivotal in driving registry data efforts for mitochondrial and inherited metabolic diseases, ensuring that patient experiences and outcomes are central to research and regulatory decision-making. Our presenters include: Sophia Zilber 🌺Board Member and Patient Registry Director, Cure Mito Foundation. Sophia brings over 20 years of experience in drug development and clinical data analysis, leading the global Leigh syndrome patient registry at the Cure Mito Foundation. Elizabeth Reynolds, Co-Founder and Executive Director, The Champ Foundation. Dr. Reynolds has spearheaded over $2 million in research grants for Single Large-scale mtDNA Deletion Syndromes and co-leads a multi-site Natural History Study and patient-registry. Amanda Klein, Executive Director, Critical Path for Lysosomal Diseases and the Alpha-1 Antitrypsin Deficiency Consortia at C-Path. Dr. Klein leads initiatives to accelerate drug development for mitochondrial and inherited metabolic diseases and is a key figure in the RDCA-DAP initiative. Don’t miss this opportunity to learn from experts about the crucial role of patient advocacy in advancing research and healthcare outcomes. 🔗 Register now to secure your spot: https://lnkd.in/eNExmF9R #CPath #PatientAdvocacy #MitochondrialDiseases #Webinar #HealthcareInnovation #DrugDevelopment #collaboration #datasharing
-